GlassScriptPhysician profile
Richard Bale
NPI 1821100223
$1,546.38
in general payments reported to CMS, 2019-2025
14 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $153 · 2021: $326 · 2022: $175 · 2023: $246 · 2024: $337 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $478.87 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.63 | 2019-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $164.02 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $143.89 | 2023-2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $96.59 | 2019-2023 | |
| Lilly USA, LLC | $79.96 | 2020-2023 | Emgality, Jardiance |
| Almatica Pharma LLC | $53.18 | 2021-2022 | |
| Eisai INC. | $41.21 | 2020 | |
| Abbvie INC. | $38.90 | 2021 | |
| Merck Sharp & Dohme LLC | $35.95 | 2019-2021 | |
| Biogen, INC. | $19.17 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $16.83 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $15.67 | 2022 | |
| Allergan, INC. | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.